口咽癌调强放疗与质子治疗后放射性骨坏死比较
这项回顾性队列研究纳入2013至2023年单中心1564例口咽鳞癌患者,比较质子治疗与调强放疗后放射性骨坏死的发生情况。结果显示质子治疗组3年骨坏死发生率显著高于调强放疗组,高级别骨坏死少见,质子治疗、同步化疗和吸烟为独立相关因素。
要点
- 质子治疗后3年任意级别骨坏死发生率6.36%,高于调强放疗的2.69%。
- 根治性治疗亚组中质子治疗骨坏死风险更高(HR 3.62,95%CI 1.85-7.09)。
- 质子治疗、同步化疗和吸烟为骨坏死的独立相关因素。
核心结论
- 在口咽鳞癌患者中,质子治疗与调强放疗相比骨坏死发生率更高,尤其在根治性治疗场景,但高级别骨坏死在两种模式下均不常见。
- 作者认为这些回顾性结果应视为探索性,需未来假设驱动研究优化剂量限制以降低骨坏死风险。
研究设计与样本
- 单中心高容量学术机构回顾性队列研究,纳入2013年1月至2023年12月连续收治的口咽鳞癌患者。
- 共纳入1564例患者,平均(SD)年龄61.5(9.6)岁,女性208例(13.3%)、男性1356例(86.7%)。
- 1389例(88.8%)接受调强放疗,175例(11.2%)接受质子治疗(均匀扫描或笔形束扫描)。
- 骨坏死诊断与分级经标准化多学科评审确定,主要结局为3年骨坏死发生率,采用Cox回归识别预测因素。
- 数据分析时间为2024年12月至2025年4月。
主要发现
- 任意级别骨坏死3年发生率为3.02%(95%CI 2.22%-4.09%)。
- 质子治疗组3年骨坏死率6.36%,调强放疗组2.69%(HR 2.62;95%CI 1.39-4.93)。
- 根治性治疗患者中,调强放疗组1210例中47例发生骨坏死(3年率2.38%;95%CI 1.61-3.51%),质子组134例中11例(3年率7.47%;95%CI 3.40-16.02%;HR 3.62;95%CI 1.85-7.09)。
- 多变量分析显示质子治疗(HR 2.92;95%CI 1.55-5.50)、同步化疗(HR 3.29;95%CI 1.03-10.50)和吸烟(HR 2.33;95%CI 1.38-3.92)与骨坏死独立相关。
- 3级及以上骨坏死发生率为0.67%,未见按放疗模式存在明显差异。
临床怎么用
- 对接受质子治疗的口咽鳞癌患者,尤其根治性治疗者,应加强颌骨骨坏死的监测与随访。
- 同步化疗和吸烟者骨坏死风险更高,治疗计划与口腔管理时需重点关注。
局限性
- 为单中心回顾性队列研究,结果应视为探索性,可能存在选择偏倚与混杂。
- 质子治疗组样本量相对较小(175例),结论需前瞻性假设驱动研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Osteoradionecrosis (ORN) is a potentially debilitating late complication of radiotherapy (RT) for head and neck cancer. While proton therapy offers superior dose conformality, its impact on ORN risk remains uncertain, particularly in patients with oropharyngeal squamous cell carcinoma (OPSCC). OBJECTIVE: To characterize the incidence, severity, and predictors of ORN in a large institutional cohort of patients with OPSCC treated with curative-intent RT, and to compare outcomes between proton therapy and intensity-modulated radiation therapy (IMRT). DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included consecutive patients with OPSCC treated from January 2013 to December 2023 at a single high-volume academic institution. Patients received either IMRT or proton therapy (uniform scanning or pencil beam scanning). ORN diagnosis and grading were determined through standardized multidisciplinary review. The primary outcome was the 3-year rate of ORN. Cox regressions identified predictors of ORN. Data were analyzed from December 2024 to April 2025. EXPOSURES: Radiotherapy modality (proton vs IMRT), patient demographic characteristics, smoking status, human papillomavirus status, tumor and/or node stage, chemotherapy, and radiation dosage. RESULTS: The analysis included 1564 patients (mean [SD] age, 61.5 [9.6] years; 208 females [13.3%] and 1356 males [86.7%]) of whom 1389 patients (88.8%) had undergone IMRT, and 175 patients (11.2%) had undergone proton-based treatment. The 3-year incidence of any-grade ORN was 3.02% (95% CI, 2.22%-4.09%). ORN rates were significantly higher after proton therapy compared with IMRT (6.36% vs 2.69% at 3 years; hazard ratio [HR], 2.62; 95% CI, 1.39-4.93). Of 1344 definitive patients, 47 of 1210 patients in the IMRT group (3-year rate, 2.38%; 95% CI, 1.61-3.51%) developed ORN vs 11 of 134 patients in the proton group (3-year rate 7.47%; 95% CI, 3.40-16.02% [HR, 3.62; 95% CI, 1.85-7.09]). On multivariable analysis, proton therapy (HR, 2.92; 95% CI, 1.55-5.50), concurrent chemotherapy (HR, 3.29; 95% CI, 1.03-10.50), and smoking (HR, 2.33; 95% CI, 1.38-3.92) were independently associated with ORN. Grade 3 or greater ORN occurred in 0.67% of patients and did not appear to differ by RT modality. CONCLUSIONS AND RELEVANCE: In this large, relatively homogeneous cohort of patients with OPSCC, proton therapy was associated with a higher rate of ORN compared with IMRT, particularly in the definitive setting, although high-grade ORN remained uncommon across both modalities. These retrospective findings should be considered exploratory and underscore the need for future hypothesis-driven studies to refine dose constraints and optimize treatment planning to mitigate ORN risk among patients with OPSCC.
引用
- Yang F, Dee EC, Singh A, et al. Osteoradionecrosis After Intensity-Modulated Radiation Therapy or Proton Therapy in Oropharyngeal Carcinoma. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 41296362. doi:10.1001/jamaoto.2025.4179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。